WealthShield Partners LLC Acquires 1,186 Shares of Eli Lilly and Company (NYSE:LLY)

by · The Markets Daily

WealthShield Partners LLC lifted its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 134.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,067 shares of the company’s stock after purchasing an additional 1,186 shares during the quarter. WealthShield Partners LLC’s holdings in Eli Lilly and Company were worth $1,110,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in LLY. Bank Julius Baer & Co. Ltd Zurich increased its holdings in shares of Eli Lilly and Company by 533,336.4% in the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 19,059,681 shares of the company’s stock worth $8,938,609,000 after purchasing an additional 19,056,108 shares during the last quarter. Norges Bank bought a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $3,416,206,000. Moneta Group Investment Advisors LLC increased its holdings in shares of Eli Lilly and Company by 102,752.2% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock worth $1,992,374,000 after purchasing an additional 5,440,731 shares during the last quarter. Morgan Stanley increased its holdings in shares of Eli Lilly and Company by 44.1% in the fourth quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock worth $4,411,740,000 after purchasing an additional 3,691,436 shares during the last quarter. Finally, Imprint Wealth LLC increased its holdings in shares of Eli Lilly and Company by 53,716.8% in the second quarter. Imprint Wealth LLC now owns 1,751,200 shares of the company’s stock worth $175,120,000 after purchasing an additional 1,747,946 shares during the last quarter. 81.38% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY opened at $618.55 on Friday. The firm has a market capitalization of $587.20 billion, a PE ratio of 112.06, a price-to-earnings-growth ratio of 1.99 and a beta of 0.31. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.05 and a quick ratio of 0.82. Eli Lilly and Company has a 1-year low of $309.20 and a 1-year high of $636.41. The company’s fifty day moving average price is $587.99 and its 200-day moving average price is $546.35.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, November 2nd. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.18. Eli Lilly and Company had a net margin of 15.55% and a return on equity of 48.12%. The firm had revenue of $9.50 billion for the quarter, compared to analyst estimates of $8.88 billion. On average, equities research analysts predict that Eli Lilly and Company will post 6.6 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 4th. Shareholders of record on Thursday, February 15th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.84%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.13. The ex-dividend date is Wednesday, February 14th. Eli Lilly and Company’s dividend payout ratio is presently 81.88%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 215,000 shares of the company’s stock in a transaction on Wednesday, October 11th. The shares were sold at an average price of $605.44, for a total value of $130,169,600.00. Following the sale, the insider now directly owns 99,768,810 shares of the company’s stock, valued at $60,404,028,326.40. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CAO Donald A. Zakrowski sold 670 shares of the stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $571.10, for a total transaction of $382,637.00. Following the sale, the chief accounting officer now directly owns 4,708 shares of the company’s stock, valued at approximately $2,688,738.80. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 215,000 shares of the stock in a transaction dated Wednesday, October 11th. The stock was sold at an average price of $605.44, for a total transaction of $130,169,600.00. Following the sale, the insider now directly owns 99,768,810 shares in the company, valued at $60,404,028,326.40. The disclosure for this sale can be found here. Over the last three months, insiders have sold 230,058 shares of company stock valued at $139,620,706. 0.13% of the stock is owned by insiders.

Wall Street Analyst Weigh In

LLY has been the topic of several research reports. UBS Group reaffirmed a “buy” rating and issued a $710.00 target price (up from $612.00) on shares of Eli Lilly and Company in a report on Friday, October 20th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Eli Lilly and Company in a research report on Wednesday, November 8th. TheStreet lowered Eli Lilly and Company from a “b” rating to a “c+” rating in a research report on Monday, December 4th. Wells Fargo & Company boosted their target price on Eli Lilly and Company from $615.00 to $650.00 and gave the company an “overweight” rating in a research report on Monday, October 9th. Finally, Truist Financial restated a “buy” rating and set a $650.00 target price on shares of Eli Lilly and Company in a research report on Wednesday, November 29th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $583.24.

View Our Latest Analysis on LLY

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Further Reading

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).